Toronto, Ontario–(Newsfile Corp. – September 15, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021. All results are reported…


Previous articleNova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
Next articleMINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry